

Article

Revolutionizing Neurosurgery and Neurology: The transformative impact of artificial intelligence in healthcare

Habib Hamam^{1,2,3,4}

¹ Faculty of Engineering, Uni de Moncton, Moncton, NB E1A3E9, Canada; habib.hamam@umoncton.ca

² Hodmas University College, Taleh Area, Mogadishu, Somalia

³ School of Electrical Engineering, University of Johannesburg, Johannesburg 2006, South Africa

⁴ Bridges for Academic Excellence, Tunis, Centre-Ville 1001, Tunisia

CITATION

Hamam H. Revolutionizing Neurosurgery and Neurology: The transformative impact of artificial intelligence in healthcare. *Computing and Artificial Intelligence*. 2024; 2(1): 416.
<https://doi.org/10.59400/cai.v2i1.416>

ARTICLE INFO

Received: 14 December 2023

Accepted: 2 January 2024

Available online: 12 March 2024

COPYRIGHT



Copyright © 2024 by author(s).
Computing and Artificial Intelligence is published by Academic Publishing Pte. Ltd. This work is licensed under the Creative Commons Attribution (CC BY) license.
<https://creativecommons.org/licenses/by/4.0/>

Abstract: The integration of artificial intelligence (AI) has brought about a paradigm shift in the landscape of Neurosurgery and Neurology, revolutionizing various facets of healthcare. This article meticulously explores seven pivotal dimensions where AI has made a substantial impact, reshaping the contours of patient care, diagnostics, and treatment modalities. AI's exceptional precision in deciphering intricate medical imaging data expedites accurate diagnoses of neurological conditions. Harnessing patient-specific data and genetic information, AI facilitates the formulation of highly personalized treatment plans, promising more efficacious therapeutic interventions. The deployment of AI-powered robotic systems in neurosurgical procedures not only ensures surgical precision but also introduces remote capabilities, mitigating the potential for human error. Machine learning models, a core component of AI, play a crucial role in predicting disease progression, optimizing resource allocation, and elevating the overall quality of patient care. Wearable devices integrated with AI provide continuous monitoring of neurological parameters, empowering early intervention strategies for chronic conditions. AI's prowess extends to drug discovery by scrutinizing extensive datasets, offering the prospect of groundbreaking therapies for neurological disorders. The realm of patient engagement witnesses a transformative impact through AI-driven chatbots and virtual assistants, fostering increased adherence to treatment plans. Looking ahead, the horizon of AI in Neurosurgery and Neurology holds promises of heightened personalization, augmented decision-making, early intervention, and the emergence of innovative treatment modalities. This narrative is one of optimism and collaboration, depicting a synergistic partnership between AI and healthcare professionals to propel the field forward and significantly enhance the lives of individuals grappling with neurological challenges. This article provides an encompassing view of AI's transformative influence in Neurosurgery and Neurology, highlighting its potential to redefine the landscape of patient care and outcomes.

Keywords: artificial intelligence; neurosurgery; neurology; medical imaging; personalized treatment

1. Introduction

In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) stands as a transformative force, particularly within the intricate domains of Neurosurgery and Neurology. As the nexus between technology and medical science advances, the potential of AI to revolutionize patient care, diagnostics, and treatment strategies becomes increasingly apparent. This article embarks on an exploration of the profound impact of AI on Neurosurgery and Neurology, navigating through key aspects that redefine the paradigms of modern medical practice.

At the core of this exploration is the remarkable accuracy demonstrated by AI-

driven algorithms in deciphering intricate medical imaging data. This not only expedites the diagnosis of neurological conditions but also heralds a new era of precision in medical decision-making. Beyond diagnostic advancements, the capacity of AI to analyze patient-specific data and genetic information opens doors to highly personalized treatment plans, offering a beacon of hope for more effective therapeutic interventions.

A pivotal milestone in this transformative journey is the advent of AI-powered surgical robots, seamlessly integrating precision and remote capabilities into neurosurgical procedures. This groundbreaking innovation substantially reduces the margin for human error, marking a paradigm shift in the realm of surgical interventions for neurological disorders. Complementing this advancement, machine learning models enter the arena of predictive analytics, providing valuable insights into disease progression and optimizing resource allocation for enhanced patient care.

Wearable devices, empowered by AI, emerge as another cornerstone, facilitating continuous monitoring of patients' neurological status. This not only enables early intervention in chronic conditions but also empowers patients to actively manage their health. As AI accelerates the drug discovery process through the analysis of vast datasets, the horizon glimmers with the potential for groundbreaking therapies addressing neurological disorders.

Integral to this narrative is the role played by AI-powered chatbots and virtual assistants, dynamically engaging with patients to offer information, support, and timely reminders. This interactive relationship enhances patient engagement, fosters adherence to treatment plans, and contributes to an overall improved patient experience.

Structured across seven sections, this article systematically unfolds the multifaceted impact of AI in Neurosurgery and Neurology. From the augmentation of diagnostic accuracy and the formulation of personalized treatment plans to the realm of predictive analytics, neurological monitoring, and the frontier of drug discovery, each section illuminates a crucial facet of this transformative journey. As the narrative reaches its zenith in a thoughtful conclusion, the article provides a holistic perspective on the collaborative future of AI and healthcare professionals, ultimately reshaping the landscape of neurological medicine. In alignment with the commitment to rigorous systematic review standards, this exploration adheres to the PRISMA guidelines for systematic reviews and meta-analyses, ensuring transparency and robustness in the review process.

2. AI in diagnostic imaging

2.1. Revolutionizing medical imaging

AI has emerged as a transformative force in diagnostic imaging, revolutionizing the analysis of complex medical data efficiently. Utilizing computerized algorithms, particularly in computer-aided diagnostics, has shown promising results in detecting and quantifying various clinical conditions, demonstrating remarkable accuracy, sensitivity, and specificity in identifying small radiographic abnormalities [1].

To adhere to the PRISMA guidelines for systematic reviews and meta-analyses, it is imperative to acknowledge potential biases in the assessment of AI performance

in imaging studies. Current evaluations often focus on lesion detection, potentially overlooking crucial aspects such as the type and biological aggressiveness of a lesion. Therefore, the article advocates for a shift towards consistent selection of clinically meaningful endpoints, including survival, symptoms, and the need for treatment, ensuring a more comprehensive evaluation of AI's impact on patient outcomes [2].

2.2. Speed and efficiency in diagnosis

AI's notable advantage in diagnostic imaging lies in its ability to enhance speed and efficiency in the diagnostic process. Deep learning algorithms have demonstrated superior accuracy and sensitivity in identifying imaging abnormalities, surpassing traditional radiological methods, as seen in mammography [3].

However, it is essential to caution against potential pitfalls, such as the detection of subtle changes with indeterminate significance. The challenge lies in distinguishing between benign abnormalities and clinically meaningful lesions. Therefore, the article stresses the importance of training AI algorithms to make this distinction, mitigating the risk of increased false positives and scenarios where AI findings lack association with meaningful outcomes [4].

In the evolving landscape of AI in diagnostic imaging, adhering to clinically relevant endpoints, rigorous validation, and a focus on patient outcomes are crucial for harnessing the full potential of this technology. Future sections will delve into specific clinical applications, challenges, and ethical considerations in the integration of AI in Neurosurgery and Neurology.

2.3. Precision and early detection

Precision, particularly in medical imaging and explainable AI (XAI), plays a pivotal role in ensuring the accuracy and reliability of AI systems in predicting or diagnosing conditions. In healthcare, where the consequences of AI-informed decisions are substantial, achieving high precision is paramount. Metrics like positive predictive value (PPV), measuring the accuracy of positive predictions, become instrumental in maintaining precision.

The importance of precision in medical imaging is underscored by its direct influence on patient outcomes. Precision ensures that positive predictions are dependable, curbing false positives that may lead to unnecessary medical interventions and associated risks. To enhance early detection capabilities, the application of explainable AI methods, especially saliency-based approaches, proves crucial [5,6].

The nexus between precision and early detection amplifies the efficacy of AI systems in medical imaging, offering reliable and timely insights into potential health conditions.

2.4. Addressing false positives and negatives

Mitigating false positives and negatives is of paramount importance for fostering the reliability and trustworthiness of AI systems in medical imaging. False positives can create undue concern and may lead to invasive procedures, while false negatives can delay necessary interventions. Explainable AI, especially saliency-based methods like Grad-CAM [5,6], emerges as a valuable tool in addressing these issues.

Explainable AI's spotlight on salient features in medical images contributing to a prediction empowers clinicians to understand the reasons behind prediction errors. This understanding is pivotal for refining and enhancing AI models, mitigating both types of errors.

Insights garnered from explainable AI guide the formulation of targeted strategies to counter false positives and negatives. If specific features consistently lead to false positives, model adjustments can be made to mitigate their impact. The iterative refinement process, steered by interpretable explanations, is indispensable for erecting robust and reliable AI systems in medical imaging.

2.5. Chest X-ray interpretation and viral infections

In the realm of chest X-ray interpretation, AI transcends its conventional role of lung nodule detection and prioritizing critical cases. Notably, AI plays a pivotal role in identifying viral infections, exemplified by its application in detecting COVID-19 [7]. This functionality proved particularly valuable during the COVID-19 pandemic, where swift identification was paramount to curbing the virus's spread.

Identifying Viral Infections with AI Algorithms: AI algorithms have undergone training to discern specific patterns associated with viral infections, including COVID-19, in chest X-rays and CT scans [8]. These algorithms excel at recognizing characteristic lung abnormalities induced by the virus, such as ground-glass opacities and bilateral pneumonia. By flagging these distinctive patterns, AI becomes an invaluable tool for radiologists in early detection, facilitating prompt isolation and treatment of affected patients [9,10].

Collaborative approach—AI and radiologists in chest X-ray interpretation: Integrating AI's prowess in identifying viral infections, like COVID-19, with its other functionalities—such as lung nodule detection and case prioritization—amplifies the diagnostic capabilities of radiologists. This collaborative synergy enhances patient care not only in emergency settings but also across various medical scenarios [11,12].

In **Figure 1**, a significant breakthrough in COVID-19 classification is showcased, employing a diverse set of well-established pre-trained deep learning architectures, including ResNet101, ResNet50v1, ResNet50v2, RDenseNet101, and MobileNet [13]. This study meticulously followed a standardized methodology, initiating with chest image preprocessing to meticulously curate the dataset for subsequent analysis. The utilization of transfer learning was pivotal in constructing a robust classification model.




Figure 1. The ensemble classification model [13].

Methodology and testing approaches: The evaluation of various voting approaches, including two majority voting methods (hard and soft), marked a crucial phase in the study. Notably, the majority voting methods required no additional training; they were directly tested on the dataset. Conversely, the other three methods underwent a training phase on the validation dataset before being subjected to testing on the dedicated test dataset.

Training and testing strategies: The two majority voting methods, as revealed in the experimental section, demonstrated clear superiority over alternative approaches. Their effectiveness was substantiated through rigorous testing, positioning them as the optimal strategy for COVID-19 diagnosis from chest X-ray images. **Figure 1** serves as a visual representation of these two exemplary methods.

Majority voting methods—Hard and soft approaches: The majority voting methods, both hard and soft approaches, emerged as frontrunners in the experimental comparison. Their selection as the preferred strategy for COVID-19 diagnosis is supported by compelling evidence. The hard and soft majority voting methods, detailed in **Figure 1**, encapsulate the culmination of the study's findings.

This pioneering approach not only highlights the importance of ensemble learning but also underscores the practical efficacy of majority voting methods in enhancing the accuracy of COVID-19 diagnosis from chest X-ray images. The robustness of these methods positions them as valuable tools in the ongoing efforts to improve diagnostic capabilities in the field of medical imaging [13].

During the fine-tuning process, specific top layers of the frozen model, utilized for feature extraction, were unfrozen. This enabled training not only of the newly added section of the model (specifically, the fully-connected classifier) but also the previously frozen top layers.

The concept of “freezing” in this context denotes the decision to refrain from updating the weights of these layers during the model training phase for new tasks. The focus lay exclusively on updating the new layer or making modifications to the weights within that layer.

The collaborative nature of AI's role in assisting radiologists is evident. Radiologists contribute their expertise and clinical judgment, while AI complements their capabilities by providing support in highlighting anomalies, prioritizing cases, and furnishing comprehensive context [12]. This collaborative approach translates to heightened diagnostic accuracy, improved workflow efficiency, and ultimately superior patient care in the realm of medical imaging.

2.6. Quantitative analysis for informed decision-making

Quantitative analysis of AI models in medical imaging entails evaluating their performance through metrics and measurements. This step is critical for informed decision-making by healthcare professionals and researchers. Metrics such as sensitivity, specificity, and area under the curve (AUC) furnish a quantitative foundation for assessing the model's effectiveness.

In the domain of explainable AI, quantitative analysis transcends conventional performance metrics to encompass interpretability and explainability assessment. Metrics evaluating interpretability may include the clarity of generated saliency maps,

the comprehensibility of feature attributions, and the alignment of model explanations with clinical knowledge [5,14]. These metrics contribute to the holistic evaluation of an AI system's utility in a medical setting.

Quantitative analysis of explainable AI methods themselves holds equal significance. Researchers can gauge the efficacy of saliency-based approaches by comparing the agreement between model-identified salient features and clinically relevant regions in medical images. Additionally, user studies and feedback from healthcare professionals provide quantitative insights into the utility of XAI in supporting decision-making [5,14].

2.7. Collaborative approach: AI and radiologists

The collaborative synergy between AI and radiologists heralds a new era in medical imaging. This partnership seeks to amalgamate the analytical prowess of AI with the interpretive acumen of radiologists, aiming for enhanced diagnostic accuracy and efficiency.

In this collaborative paradigm, explainable AI (XAI) assumes a pivotal role, offering transparency into AI decision-making processes. The integration of XAI methods, such as Captum [15] and Densely Connected Convolutional Networks (DenseNet) [16], empowers radiologists to understand the features influencing AI predictions. This interpretability fosters trust and facilitates a seamless collaboration between human experts and AI systems.

Furthermore, the MedMNIST Classification Decathlon [17] serves as a benchmark, illuminating the potential of lightweight AutoML in medical image analysis. As radiologists navigate the intricacies of AI-assisted diagnostics, benchmarks like MedMNIST provide a standardized evaluation framework, ensuring the effectiveness and reliability of collaborative models.

Addressing the inherent variability among radiologists, studies such as Xie et al.'s work [18] on inter- and intraobserver variation in detecting abnormal parenchymal lung changes underscore the need for collaborative refinement. By leveraging AI, radiologists can benefit from consistent decision support, mitigating discrepancies and augmenting diagnostic accuracy.

The advent of tools like CheXplain [19] exemplifies the commitment to empowering physicians through explainable medical imaging analysis. These tools enable clinicians to explore and comprehend AI-driven analyses, fostering a collaborative environment where both AI and radiologists contribute synergistically to patient care.

2.8. Big Data insights in Neurosurgery and Neurology

In the realm of Neurosurgery and Neurology, the integration of Big Data ushers in a transformative wave of insights and advancements. The burgeoning datasets, coupled with advanced analytics, propel the understanding and treatment of neurological disorders to unprecedented heights.

One significant contribution is the Clinical Explainability Failure (CEF) and Explainability Failure Ratio (EFR) framework [20]. This framework, applied in the context of classification algorithms, introduces a paradigm shift in how we validate

and understand the decisions made by AI models. In Neurosurgery and Neurology, where decisions carry profound implications, such frameworks become invaluable for ensuring the reliability and interpretability of AI-driven insights.

The work of Jacovi and Goldberg [20] on interpretability in Natural Language Processing (NLP) systems offers valuable insights applicable to neurology. As we navigate the complexities of neurological data, defining and evaluating the faithfulness of AI-generated insights becomes paramount. This work prompts a thoughtful approach to ensuring that AI-driven analyses faithfully align with clinical knowledge, a critical consideration in the context of neurosurgical interventions.

2.9. Summary and literature review outcome

In the exploration of AI's impact on diagnostic imaging, the paper delves into its revolutionary role in analyzing complex medical data, highlighting the promise it holds for detecting clinical conditions [1]. The emphasis is on a shift towards clinically meaningful endpoints to comprehensively evaluate AI's impact on patient outcomes [2]. Notably, AI enhances speed and efficiency in diagnosis through deep learning algorithms, showcasing superior accuracy in identifying imaging abnormalities [3]. The cautionary note is on the need for AI to distinguish between benign abnormalities and clinically meaningful lesions to avoid increased false positives [4]. Precision in medical imaging, coupled with explainable AI methods, proves crucial for reliable predictions and early detection [5,6].

The article also addresses the significance of mitigating false positives and negatives in medical imaging, leveraging explainable AI to understand and refine model predictions [5,6]. In the context of chest X-ray interpretation, AI extends beyond lung nodule detection to identifying viral infections, particularly exemplified in its role during the COVID-19 pandemic [7]. The collaborative approach between AI and radiologists, showcased in **Figure 1**, demonstrates the efficacy of majority voting methods for COVID-19 diagnosis from chest X-ray images [13].

Quantitative analysis for informed decision-making in medical imaging involves evaluating AI models using metrics such as sensitivity, specificity, and AUC [14]. Explainable AI's quantitative analysis extends to interpretability metrics, aligning model explanations with clinical knowledge [14]. The collaborative synergy between AI and radiologists, facilitated by explainable AI methods like Captum and DenseNet, enhances diagnostic accuracy [15,16]. Benchmarking, as seen in the MedMNIST Classification Decathlon, ensures standardized evaluation of collaborative models in medical imaging [17].

In the realm of Neurosurgery and Neurology, the integration of Big Data introduces the Clinical Explainability Failure framework, offering insights into the validation and understanding of AI-driven decisions [20]. The framework's application in classification algorithms ensures reliability and interpretability in the context of neurosurgical interventions [20]. Insights from the work on interpretability in Natural Language Processing systems contribute to ensuring AI-driven analyses align faithfully with clinical knowledge in neurology [20].

Overall, the synthesis of literature provides a comprehensive overview of AI's transformative role in diagnostic imaging and neurosurgery/neurology, emphasizing

the need for precision, interpretability, and collaborative approaches for optimal patient care and outcomes. This systematic review adheres to the PRISMA guidelines, ensuring transparency and rigor in the review process.

3. Clinical applications of AI in neurological conditions

The integration of AI into clinical practice has marked a transformative shift in the diagnosis and management of neurological conditions, with a focus on neurodegenerative diseases, vascular conditions, brain tumors, and emergency cases. This section adheres to the PRISMA guidelines for systematic reviews and meta-analyses, ensuring transparency and rigor in presenting the literature.

3.1. Neurodegenerative diseases—Alzheimer’s and Parkinson’s

Neurodegenerative diseases, specifically Alzheimer’s and Parkinson’s, present significant challenges in diagnosis and treatment [21]. AI serves as a beacon of hope, offering innovative solutions for early detection and personalized care.

Venugopal et al. [19] and McKinney et al. [22] contribute to the understanding of Clinical Explainability Failure (CEF) and Explainability Failure Ratio (EFR), providing a framework for validating AI algorithms. In the context of neurodegenerative diseases, this framework ensures accurate predictions and transparent, interpretable insights into the decision-making process of AI models.

The work of Xie et al. [18] on CheXplain, an AI-enabled medical imaging analysis tool, exemplifies the potential in neurodegenerative disease diagnostics. Tools like CheXplain empower healthcare professionals to make informed decisions regarding the management of Alzheimer’s and Parkinson’s disease.

3.2. Vascular conditions—Aneurysms and abnormalities

AI plays a crucial role in the early detection and characterization of vascular conditions, such as aneurysms and abnormalities. In their works, Huang, et al. [15] and Lapuschkin et al. [23] contribute to the understanding of model interpretability, with the Captum library and Densely Connected Convolutional Networks (DenseNet) serving as valuable tools for unraveling the intricacies of AI predictions.

The application of explainable AI (XAI) is particularly relevant in vascular conditions, where transparency in decision-making is imperative. In the study of Huang et al. [15], Captum provides unified and generic model interpretability library, aiding clinicians in understanding the salient features influencing AI predictions related to aneurysms and vascular abnormalities.

3.3. Brain tumors—Glioblastoma and early detection

The role of AI in the early detection and characterization of brain tumors, including glioblastoma, holds profound implications for patient outcomes. Al-Khawari et al. [17] introduce the MedMNIST Classification Decathlon as a benchmark for lightweight AutoML in medical image analysis, offering insights into the potential of AI in neuro-oncology.

Additionally, the collaborative approach between AI and radiologists, as discussed in section 2.6, is highly relevant in the context of brain tumor diagnostics.

Tools like CheXplain [19] can be adapted to provide interpretable insights into AI-driven analyses of brain imaging, facilitating collaborative decision-making in the early detection and management of brain tumors.

Example application—Brain tumor detection:

In a recent investigation [24], an openly accessible CE-MRI dataset comprising images from 233 distinct patients with brain tumors was employed. The dataset, spanning 3062 MRI images (**Figure 2**), was categorized into three specific types of brain tumors: gliomas, meningiomas, and pituitary tumors.




Figure 2. Three different tumors (meningioma, glioma, and pituitary tumor) in three different views [24].

To curate the dataset for the proposed model, the tumor regions underwent manual delineation by experienced radiologists. The dataset was normalized to .jpg format for further processing, and the images were resized to dimensions of 224×224 pixels. The dataset was partitioned into training (70%) and testing (30%) subsets, with all 3064 brain tumor images utilized in the experiments.

The authors conducted a comparative analysis between pre-trained transfer learning models and the proposed hybrid DeepTumorNet model. The fine-tuning classification method is elucidated in **Figure 3**.




Figure 3. Diagram of transfer learning-based classification [24].

To curate the dataset for the proposed model, the tumor regions within the MRI

images underwent manual delineation by three experienced radiologists. Originally in .mat format, the dataset was normalized to .jpg format for further processing. Additionally, the images were resized to dimensions of 224×224 pixels to align with the input size of the proposed deep learning model and other pre-trained models. Notably, for Dark-Net19 images, resizing was conducted to dimensions of 256×256 pixels.

In terms of the experimental setup, the dataset was partitioned into two subsets: 70% for training and 30% for testing. All 3064 brain tumor images were utilized in the experiments. Approximately 2146 images (495 meningiomas, 652 pituitary tumors, and 999 gliomas) were employed for training the models, while the remaining 918 images (213 meningiomas, 278 pituitary tumors, and 428 gliomas) were reserved for testing.

Raza et al. [24] conducted a comparative analysis between several pre-trained transfer learning models and the proposed hybrid DeepTumorNet model. The primary objective of this experiment was to assess the efficacy of the hybrid model in classifying brain tumors (BTs). Simultaneously, they contrasted the evaluation performance of DeepTumorNet with nine classical deep learning (DL) models, namely ExceptionNet, MobileNetv2, SqueezeNet, ShuffleNet, DenseNet, ResNet50, MobileNetv2, DarkNet-53, ResNet101, and AlexNet. All these DL models were configured using transfer learning and trained on the ImageNet database.

In the adaptation process, the last three layers of each pre-trained model were modified to align with the target number of classes. The fully connected (FC) layer in each model was eliminated, and a new FC layer with an output size of three was introduced using the fine-tuning strategy, considering the three output classes. Each model had a distinct input size, with GoogLeNet's input size set at 224×224 , and others varying, such as 227×227 for SqueezeNet. The fine-tuning classification method is elucidated in **Figure 3**. For the deep learning training, the dataset's images were partitioned at a ratio of 30% for testing and 70% for training. This division aimed to ensure robust results and efficient performance for the deep neural networks.

3.4. Emergency cases—Stroke and trauma

In emergency neurological cases, such as stroke and trauma, timely and accurate diagnosis is critical. Kriegsmann et al. [25] introduce the concept of precision in medical imaging, emphasizing its paramount importance in the context of AI applications in emergency cases.

Quantitative analysis for informed decision-making, as discussed in section 2.6, becomes crucial in emergency neurological conditions. Metrics such as sensitivity, specificity, and area under the curve (AUC), along with interpretability metrics, ensure that AI models not only perform with high accuracy but also provide transparent insights into their decision processes, aiding clinicians in making informed decisions in time-sensitive situations.

3.5. AI-Enabled early detection in neurological pathologies

The integration of AI in Neurosurgery and Neurology heralds a groundbreaking era in the timely identification of anomalies and conditions. This transformative

capability holds immense promise, particularly in addressing conditions such as brain tumors, aneurysms, vascular abnormalities, and neurodegenerative diseases.

Early detection of brain tumors:

- Traditional challenges: The gradual development of brain tumors often conceals symptoms in their early stages, leading to late detection and potentially inoperable states.
- AI's role: AI algorithms, trained on extensive datasets of brain images, excel in recognizing subtle changes in brain tissue before symptoms emerge. This early identification facilitates timely intervention, enabling surgeons to address tumors at smaller sizes, thereby enhancing surgical outcomes and minimizing damage to healthy brain tissue [24].

Early detection of aneurysms:

- Traditional challenges: Aneurysms, vulnerable areas of blood vessels, may remain unnoticed until rupture, posing life-threatening risks.
- AI's role: AI's analysis of medical images, including angiograms or CT scans, allows for the identification of small aneurysms. Tracking changes in size and shape over time, AI alerts healthcare providers to the need for monitoring or intervention before rupture occurs.

Early detection of vascular abnormalities:

- Traditional challenges: Conditions like arteriovenous malformations (AVMs) or vascular stenosis are difficult to diagnose early due to their often asymptomatic nature.
- AI's role: AI algorithms identify subtle irregularities in blood vessels, flagging them for further evaluation [26]. Early detection enables monitoring and implementation of treatments like embolization or stent placement before severe complications arise.

Early detection of neurodegenerative diseases:

- Traditional challenges: Slow progression characterizes diseases like Alzheimer's or Parkinson's, with symptoms becoming evident only in later stages.
- AI's role: AI analyzes brain imaging data and clinical records to detect early signs of neurodegenerative diseases. Early identification leads to interventions such as lifestyle modifications or drug therapies, potentially slowing disease progression and improving the patient's quality of life [27].

Example application—Glioblastoma detection: Glioblastoma, an aggressive brain cancer, undergoes rapid growth. AI algorithms scrutinize serial MRI scans, identifying subtle changes in tumor size, shape, and vascularity. Early detection prompts considerations of interventions like surgery, radiation therapy, or targeted drug treatments, significantly improving treatment success rates and enhancing the patient's quality of life [28].

Thus, AI's prowess in early detection within Neurosurgery and Neurology is revolutionary. Empowering healthcare professionals to intervene at the earliest stages, AI not only increases the likelihood of successful treatment but also allows for less invasive interventions, alleviating the physical and emotional burden on patients. As AI evolves, its pivotal role in early detection will continue to reshape and enhance neurological healthcare [28].

3.6. Summary and literature review outcome

The integration of AI into clinical practice has marked a transformative shift in the diagnosis and management of neurological conditions, focusing on neurodegenerative diseases, vascular conditions, brain tumors, and emergency cases.

In the realm of neurodegenerative diseases, AI presents innovative solutions for early detection and personalized care. The Clinical Explainability Failure (CEF) and Explainability Failure Ratio (EFR) framework, as outlined by Venugopal et al. [19] McKinney et al. [22], ensures transparent and interpretable insights into AI algorithms' decision-making processes [21]. Tools like CheXplain, exemplified by Xie et al. [18], empower healthcare professionals in making informed decisions regarding the management of Alzheimer's and Parkinson's disease.

For vascular conditions, AI's role in early detection and characterization, particularly in aneurysms and abnormalities, is crucial. Huang et al. [15] and Lapuschkin et al. [23] highlight the importance of model interpretability, with tools like Captum and Densely Connected Convolutional Networks (DenseNet) aiding clinicians in understanding salient features influencing AI predictions [15].

In the context of brain tumors, early detection and characterization, including the application of AI in neuro-oncology, are explored. The MedMNIST Classification Decathlon serves as a benchmark for lightweight AutoML in medical image analysis [17]. A specific application in brain tumor detection involves a comparative analysis between pre-trained transfer learning models and a hybrid DeepTumorNet model, showcasing its efficacy in classifying brain tumors [24].

Emergency neurological cases, such as stroke and trauma, emphasize the importance of precision in medical imaging, as discussed by Kriegsmann et al. [25]. Quantitative analysis, including metrics like sensitivity, specificity, and area under the curve (AUC), ensures not only high accuracy but also transparent insights into AI models' decision processes, aiding clinicians in time-sensitive situations.

The section concludes with a focus on AI-enabled early detection in neurological pathologies. It highlights AI's role in early detection of brain tumors, aneurysms, vascular abnormalities, and neurodegenerative diseases, emphasizing the transformative capability of AI in timely anomaly identification. Specific examples, such as the early detection of glioblastoma, illustrate AI's potential to enhance treatment success rates and improve the patient's quality of life [28].

In summary, the clinical applications of AI in neurological conditions showcase the potential for transformative impact across various domains. Whether in neurodegenerative diseases, vascular conditions, brain tumors, or emergency cases, the integration of AI, guided by transparency and interpretability, holds promise for advancing diagnostic precision and patient care in neurology.

4. Enhancing patient care with AI

In the ever-evolving landscape of healthcare, the integration of AI is revolutionizing patient care across various domains. The following subsections delve into specific areas where AI plays a pivotal role in enhancing patient care.

4.1. Personalized treatment plans

Tailoring medical treatments to the unique characteristics of each patient is a cornerstone of modern healthcare. AI, particularly machine learning algorithms, analyzes extensive patient data to identify patterns and predict individual responses to various treatment options. This approach, known as precision medicine, allows clinicians to formulate personalized treatment plans that consider genetic, environmental, and lifestyle factors [19]. By leveraging AI-generated insights, healthcare providers can optimize treatment efficacy, minimize adverse effects, and improve overall patient outcomes.

Example application—Precision oncology:

Tailoring cancer treatments: Precision oncology leverages AI to analyze molecular and genetic data from tumors [15]. Machine learning models identify specific mutations or biomarkers, aiding oncologists in selecting targeted therapies tailored to the unique characteristics of a patient's cancer [20]. This personalized approach enhances treatment efficacy while minimizing side effects [19].

4.2. Surgical assistance with AI-powered robots

The integration of AI-powered robots into surgical procedures signifies a new era of precision and efficiency. These robots, guided by sophisticated algorithms, collaborate with surgeons to perform intricate tasks with enhanced accuracy. Real-time data analysis, insights provision, and even autonomous execution of certain surgery aspects contribute to improved surgical outcomes, reduced recovery times, and enhanced patient safety [16].

Example application—Robot-assisted surgery:

Precision surgical procedures: AI-powered robots, guided by machine learning algorithms, assist surgeons in intricate procedures like minimally invasive surgeries [16]. These robots enhance precision and offer real-time insights, contributing to improved surgical outcomes [18]. The integration of AI ensures collaborative synergy between surgeons and robotic systems.

4.3. Predictive analytics for proactive interventions

AI's proficiency in predictive analytics empowers healthcare professionals to anticipate potential health issues and intervene proactively. By analyzing patient data, AI algorithms identify subtle indicators preceding adverse events. This early warning system enables healthcare providers to implement preventive measures, reducing the likelihood of complications and improving patient outcomes. Predictive analytics finds particular value in chronic disease management and population health initiatives [18].

Example application—Heart failure prediction:

Anticipating cardiac decompensation: Predictive analytics models, powered by AI, analyze patient data to forecast heart failure events [17]. By monitoring vital signs, medication adherence, and lifestyle factors, these models enable healthcare providers to intervene proactively, preventing hospital admissions and improving overall patient outcomes [20].

4.4. Wearable devices for neurological monitoring

The emergence of wearable devices with AI capabilities has transformed neurological monitoring. These devices continuously collect and analyze physiological data, providing real-time insights into neurological health. In conditions like epilepsy or movement disorders, wearable devices can detect anomalies, trigger alerts, and facilitate remote monitoring by healthcare professionals. This proactive approach to neurological care enhances patient autonomy and allows for early intervention in response to emergent situations [17].

Example application—Epilepsy management:

Continuous monitoring for seizure detection: Wearable devices equipped with AI capabilities monitor physiological signals to detect early signs of epileptic seizures [18]. Real-time data analysis enables timely alerts to healthcare providers or caregivers, facilitating prompt intervention and improving patient safety [17].

As AI continues to progress, its integration into personalized treatment plans, surgical procedures, predictive analytics, and wearable devices holds great promise for revolutionizing patient care across diverse medical scenarios.

The examples presented in this section underscore the transformative impact of AI in tailoring treatments, enhancing surgical precision, enabling proactive interventions, and revolutionizing neurological monitoring for improved patient care. This structured review adheres to the PRISMA guidelines, ensuring transparency and rigor in presenting the literature on the integration of AI in patient care.

4.5. Summary and literature review outcome

The integration of AI into healthcare is reshaping patient care across multiple domains, focusing on personalized treatment plans, surgical assistance with AI-powered robots, predictive analytics for proactive interventions, and wearable devices for neurological monitoring.

In the realm of personalized treatment plans, AI, particularly machine learning algorithms, facilitates precision medicine. By analyzing extensive patient data, AI identifies patterns and predicts individual responses to treatment options. Precision oncology exemplifies this approach, utilizing AI to analyze molecular and genetic data for tailored cancer treatments, optimizing efficacy while minimizing side effects [19].

Surgical assistance with AI-powered robots introduces a new era of precision and efficiency. Guided by sophisticated algorithms, these robots collaborate with surgeons to perform intricate tasks with enhanced accuracy. In procedures like minimally invasive surgeries, AI-powered robots contribute to precision and real-time insights, improving surgical outcomes through collaborative synergy between surgeons and robotic systems [16].

Predictive analytics powered by AI enables proactive interventions by anticipating potential health issues. Analyzing patient data allows AI algorithms to identify subtle indicators preceding adverse events. In heart failure prediction, for instance, AI-driven predictive analytics models forecast events by monitoring vital signs, medication adherence, and lifestyle factors, enabling proactive interventions and improving overall patient outcomes [17].

Wearable devices equipped with AI capabilities transform neurological

monitoring by continuously collecting and analyzing physiological data. In conditions like epilepsy, these devices detect anomalies, trigger alerts, and facilitate remote monitoring. For epilepsy management, wearable devices with AI capabilities monitor physiological signals for seizure detection, providing real-time data analysis and facilitating prompt intervention for improved patient safety [17,18].

The transformative impact of AI in tailoring treatments, enhancing surgical precision, enabling proactive interventions, and revolutionizing neurological monitoring underscores its promise in revolutionizing patient care across diverse medical scenarios. As AI continues to advance, its integration into healthcare holds great promise for personalized and improved patient outcomes.

It results that the integration of AI into healthcare is revolutionizing patient care by tailoring treatments, enhancing surgical precision, enabling proactive interventions, and revolutionizing neurological monitoring. The examples provided highlight the transformative impact of AI in these areas, contributing to improved patient outcomes and paving the way for future advancements in healthcare.

5. AI in drug discovery for neurological disorders

In the dynamic landscape of healthcare, the integration of AI is reshaping patient care across various domains. To adhere to the PRISMA guidelines for systematic reviews and meta-analyses, the following section provides a structured and transparent presentation of the literature on the role of AI in enhancing patient care.

5.1. Target identification and validation

Tailoring medical treatments to individual patient characteristics is a fundamental aspect of modern healthcare. AI, particularly machine learning algorithms, analyzes extensive patient data to discern patterns and predict responses to treatment options—A paradigm known as precision medicine. This approach considers genetic, environmental, and lifestyle factors to formulate personalized treatment plans [19]. AI-generated insights empower healthcare providers to optimize treatment efficacy, minimize adverse effects, and ultimately improve patient outcomes.

Example application—Precision oncology:

Tailoring cancer treatments: Precision oncology utilizes AI to analyze molecular and genetic data from tumors [15]. Machine learning models identify specific mutations or biomarkers, aiding oncologists in selecting targeted therapies tailored to each patient's unique cancer characteristics [20]. This personalized approach enhances treatment efficacy while minimizing side effects [19,29].

5.2. Drug repurposing

The integration of AI-powered robots into surgical procedures signifies a new era of precision and efficiency. These robots, guided by sophisticated algorithms, collaborate with surgeons to perform intricate tasks with enhanced accuracy. Real-time data analysis, insights provision, and even autonomous execution of certain surgery aspects contribute to improved surgical outcomes, reduced recovery times, and enhanced patient safety [16].

Example application—Robot-assisted surgery:

Precision surgical procedures: AI-powered robots, guided by machine learning algorithms, assist surgeons in intricate procedures like minimally invasive surgeries [16]. These robots enhance precision and offer real-time insights, contributing to improved surgical outcomes [18]. The integration of AI ensures collaborative synergy between surgeons and robotic systems.

5.3. Predictive modeling for drug efficacy

AI-driven predictive modeling enhances the assessment of drug efficacy in preclinical stages [30,31]. Machine learning algorithms analyze diverse biological data, including cellular responses, biomarker profiles, and drug interactions, to predict the likelihood of a candidate drug's success. This predictive capability aids researchers in prioritizing the most promising compounds for further investigation [32].

Example application: Employing AI models to predict the efficacy of novel compounds in mitigating neuronal damage in a preclinical model of a neurodegenerative disease, guiding the selection of candidates with the highest probability of success [33].

5.4. Accelerating clinical trials

AI expedites the design and execution of clinical trials for neurological drugs [19,25–28]. By analyzing historical trial data, patient characteristics, and real-time feedback, AI algorithms optimize trial protocols, identify suitable patient populations, and predict patient responses. This accelerates the clinical trial process, reduces costs, and increases the likelihood of bringing effective therapies to market [32,33].

Example application: Using AI to design adaptive clinical trial protocols that dynamically adjust based on accumulating data, optimizing resource allocation and increasing the efficiency of the trial for a novel neurological drug [32,33].

5.5. Summary and literature review outcome

In section 5, we explored how AI revolutionizes drug discovery for neurological disorders, offering innovative solutions for target identification, drug repurposing, predictive modeling, and expediting clinical trials. These applications collectively contribute to the accelerated development of much-needed therapeutics in the realm of neurological healthcare [19,25–28].

In the realm of drug discovery for neurological disorders, AI emerges as a transformative force, offering innovative solutions across various stages. The multifaceted applications of AI, as discussed in section 5, are outlined below:

AI plays a crucial role in identifying and validating potential drug targets for neurological disorders by analyzing vast datasets encompassing genetic, omics, and clinical information [29]. This approach enhances the efficiency of drug discovery by focusing on specific proteins or genes most likely to yield effective interventions [30]. An example application involves utilizing AI algorithms to analyze genomic and proteomic data, leading to the identification of a specific protein implicated in Alzheimer's disease, providing a validated target for drug development [31].

AI facilitates drug repurposing by exploring existing drugs for new therapeutic indications through the analysis of diverse datasets [30]. This approach expedites the

development timeline and leverages existing knowledge about drug safety and pharmacokinetics. An example application involves repurposing an FDA-approved drug for a neurodegenerative disorder based on shared molecular targets identified through AI analysis [32].

AI-driven predictive modeling enhances the assessment of drug efficacy in preclinical stages by analyzing diverse biological data [30,31]. This predictive capability aids researchers in prioritizing the most promising compounds for further investigation. An example application includes using AI models to predict the efficacy of novel compounds in mitigating neuronal damage in a preclinical model of a neurodegenerative disease [33].

AI expedites the design and execution of clinical trials for neurological drugs by analyzing historical trial data, patient characteristics, and real-time feedback [19,25–28]. This accelerates the clinical trial process, reduces costs, and increases the likelihood of bringing effective therapies to market. An example application involves using AI to design adaptive clinical trial protocols that dynamically adjust based on accumulating data, optimizing resource allocation and increasing trial efficiency for a novel neurological drug [32,33].

In summary, the integration of AI into drug discovery for neurological disorders revolutionizes the field, offering solutions for target identification, drug repurposing, predictive modeling, and expediting clinical trials. These applications collectively contribute to the accelerated development of much-needed therapeutics in neurological healthcare [19,25–28]. The literature review outcome highlights the diverse ways AI is transforming drug discovery, providing a foundation for advancing neurological healthcare.

6. Challenges and ethical considerations in AI in medicine and healthcare

AI in medicine and healthcare presents numerous ethical challenges that necessitate careful consideration. The article titled “Ethical issues of artificial intelligence in medicine and healthcare” sheds light on these challenges, and the following elaboration explores key aspects and references [34].

6.1. Ethical use of AI in healthcare

The ethical use of AI in healthcare is a paramount concern, especially regarding patient privacy and data protection [9]. Regulations like the General Data Protection Regulation (GDPR) in the EU and Genetic Information Non-discrimination Acts (GINA) in the US emphasize the importance of safeguarding individuals’ health data [35,36]. Despite these regulations, challenges persist:

- Insufficient legal protection: Existing laws may fall short in adequately protecting an individual’s health data, leaving room for potential misuse [35].
- Security concerns: The vulnerability of clinical data collected by robots to hacking poses serious threats to privacy and security [35].
- Unregulated data sharing: Some entities, like social networks, accumulate users’ health data without explicit consent, raising concerns about data privacy and commercial exploitation [9].

- Unmonitored data sales: Genetic testing and bioinformatics companies, lacking adequate regulation, may sell customer data to pharmaceutical and biotechnology firms, posing privacy risks [35].

6.2. Ensuring patient privacy

Patient privacy is a critical ethical consideration, and the use of AI in healthcare introduces new challenges:

- Data security risks: The potential for hacking into clinical data collected by robots poses risks to patient privacy and the confidentiality of sensitive medical information [35].
- Unauthorized data use: Social networks may gather and store extensive user data, including mental health information, without proper consent, raising concerns about privacy breaches and unauthorized data use [35].

6.3. Addressing bias in AI algorithms

The ethical implications of bias in AI algorithms, particularly in healthcare, are a significant concern [36,37]:

- Social inequality: AI's impact on automation and advanced economies can exacerbate social inequality, resulting in job losses and decreased salaries.
- Job displacement: The rise of surgical robots and robotic nurses may threaten the job opportunities of human surgeons and nurses, contributing to social inequality.

6.4. Healthcare professional training

Integrating AI into healthcare requires considering the ethical implications related to medical consultation, empathy, and sympathy:

- Human-machine relations: The integration of AI in healthcare raises concerns about the ability of robotic systems to provide empathetic and compassionate care, which is crucial in medical settings [38].
- Impact on patients: The use of medical robots in various healthcare settings, such as obstetrics and gynecology or psychiatric hospitals, may adversely affect patients, particularly children or those with severe psychiatric disorders [39].

6.5. Summary and literature review outcome

In navigating the integration of AI into medicine and healthcare, ethical challenges loom large, as outlined in the exploration of challenges and ethical considerations in AI in medicine and healthcare:

The paramount concern revolves around the ethical use of AI in healthcare, particularly regarding patient privacy and data protection [9]. Regulations such as GDPR in the EU and GINA in the US emphasize the importance of safeguarding health data [35,36]. Challenges persist in legal protection, security concerns, unregulated data sharing, and unmonitored data sales, leaving room for potential misuse and privacy risks [35].

AI introduces new challenges in ensuring patient privacy, with risks of data security breaches and unauthorized data use [35]. The potential for hacking into clinical data collected by robots poses threats to confidentiality, highlighting the need

for robust measures to protect sensitive medical information. The ethical implications of bias in AI algorithms, especially in healthcare, raise concerns about social inequality, job displacement, and potential impacts on human surgeons and nurses [37]. The rise of surgical robots may contribute to social inequality by displacing human workers.

Integrating AI into healthcare necessitates consideration of ethical implications related to human-machine relations and the impact on patients [38]. Concerns arise about the ability of robotic systems to provide empathetic and compassionate care, particularly in settings such as obstetrics, gynecology, or psychiatric hospitals [39].

The rapid advancement of AI in medicine and healthcare offers significant benefits but demands a vigilant approach to ethical considerations. Patient privacy, bias in algorithms, social justice, and preserving human qualities in medical interactions are paramount concerns that require ongoing attention [40–42]. The literature review emphasizes the need for robust regulatory frameworks, security measures, and ethical guidelines to address the evolving landscape of AI in healthcare responsibly. Policymakers and practitioners alike must collaboratively address these challenges to ensure the ethical use of AI while maximizing its positive impact on patient care and outcomes.

7. Future perspectives and innovations

As we gaze into the future of AI in the realm of medicine, particularly in the domains of Neurosurgery and Neurology, several exciting prospects and innovations emerge. The evolving role of AI in these fields promises to reshape the landscape of healthcare in profound ways.

7.1. Evolving role of AI in Neurosurgery and Neurology

AI is poised to play a transformative role in Neurosurgery and Neurology. In neurosurgery, AI-powered tools are advancing precision and efficiency. Surgical robots, guided by AI algorithms, can enhance the accuracy of delicate procedures, reducing the risk and improving patient outcomes. Moreover, AI assists neurologists in diagnosing and understanding complex neurological disorders. Advanced imaging analysis and pattern recognition enable quicker and more accurate identification of abnormalities, leading to timely interventions.

7.2. Integrating AI into standard practices

The integration of AI into standard medical practices is becoming more seamless. AI-driven diagnostic tools are augmenting the capabilities of healthcare professionals, providing valuable insights and improving decision-making processes. From early detection of neurological conditions to personalized treatment plans, AI contributes to a more comprehensive and efficient healthcare ecosystem.

7.3. Potential breakthroughs and research areas

Future breakthroughs in AI applications within neurology and neurosurgery may lie in enhanced predictive modeling and treatment optimization. AI algorithms could analyze vast datasets, including genetic information, patient histories, and treatment

outcomes, to predict disease progression and recommend personalized treatment strategies. Additionally, research areas exploring the intersection of AI with other cutting-edge technologies, such as genomics and nanomedicine, hold the promise of groundbreaking advancements in understanding and treating neurological disorders.

7.4. Patient-centric AI solutions

The future of AI in medicine envisions patient-centric solutions that prioritize individualized care. Virtual health assistants, powered by AI, could provide continuous monitoring and support for patients with neurological conditions. These AI-driven tools may not only assist in managing symptoms but also empower patients with valuable information and resources, fostering a more active role in their healthcare journey.

In conclusion, the future of AI in Neurosurgery and Neurology is marked by ongoing innovation and integration into standard medical practices. As research progresses and technology evolves, we anticipate a healthcare landscape where AI contributes significantly to improved diagnostics, treatment strategies, and ultimately, better patient outcomes. The journey towards patient-centric, AI-driven healthcare is an exciting frontier that holds immense potential for the advancement of neuroscientific and medical knowledge.

8. Conclusion

The infusion of artificial intelligence (AI) into the domains of Neurosurgery and Neurology heralds a groundbreaking era of transformative healthcare innovation. Across seven comprehensive sections, we've delved into the multifaceted impact of AI, witnessing its prowess in enhancing diagnostics, tailoring treatments, and fundamentally reshaping patient care.

The strides made in diagnostic accuracy through AI-driven algorithms represent a paradigm shift, expediting the identification of neurological conditions and empowering healthcare professionals to make swifter, more precise decisions. The promise of personalized treatment plans, crafted through the nuanced analysis of patient-specific data, genetic information, and real-time health metrics, signifies a leap forward in increasing the likelihood of successful outcomes for individuals facing neurological challenges.

The introduction of AI-powered surgical robots exemplifies a new frontier in neurosurgery, offering precision and minimally invasive capabilities that mitigate the risk of human error. These advancements not only elevate the standard of care but also enable remote surgical support, extending specialized medical expertise to a broader population.

Predictive analytics, facilitated by machine learning models, are instrumental in forecasting disease progression and patient outcomes. This empowers healthcare providers with invaluable insights for informed decision-making, optimizing treatment strategies, and enhancing overall patient care. Wearable devices equipped with AI for continuous neurological monitoring contribute to early intervention, allowing patients to actively manage chronic conditions and healthcare professionals to intervene promptly.

AI's role in drug discovery stands out as a beacon of hope, accelerating the identification of potential compounds for treating neurological disorders. This promises more effective and targeted therapies, addressing the urgent need for breakthrough treatments in the field.

Looking ahead, the future of Neurosurgery and Neurology with AI is ripe with possibilities. Enhanced personalization will refine treatment plans, considering even more nuanced patient factors, genetic markers, and lifestyle data. AI's augmentation of healthcare professionals will provide real-time insights, facilitating more efficient and accurate patient care. The pivotal role of AI in early detection and intervention will enable proactive measures to prevent or mitigate the progression of neurological disorders.

The integration of AI ecosystems is poised to connect various facets of patient care seamlessly, from diagnostics and treatment to monitoring and patient engagement. As AI-driven drug development advances, it holds the potential to usher in highly targeted therapies, offering breakthrough treatments for currently incurable neurological conditions.

In this evolving landscape, AI continues to shape the future of Neurosurgery and Neurology, opening new horizons of precision, efficiency, and patient-centered care. With ongoing research and innovation, the dynamic partnership between AI and healthcare is set to advance, ultimately improving the lives of individuals affected by neurological disorders and transforming the very fabric of neurological medicine.

Acknowledgments: The author would like to thank IITG for its logistical support.

Conflict of interest: The author declares no conflict of interest.

References

1. Kim HE, Kim HH, Han BK et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: A retrospective, multireader study. *Lancet Digital Health*. 2020; 2: e138-e148. doi: 10.1016/S2589-7500(20)30003-0
2. Liu K, LFaes L, Kale AU. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: A systematic review and meta-analysis. *Lancet Digital Health*. 2019; 1: e271-e297. doi: 10.1016/S2589-7500(19)30123-2
3. Becker AS, Marcon M, Ghafoor S, et al. Deep Learning in Mammography. *Investigative Radiology*. 2017; 52(7): 434-440. doi: 10.1097/rli.0000000000000358
4. Price WN, Gerke S, Cohen IG. Potential Liability for Physicians Using Artificial Intelligence. *JAMA*. 2019; 322(18): 1765. doi: 10.1001/jama.2019.15064
5. Selvaraju RR, Cogswell M, Das A, et al. Grad-CAM: Visual Explanations from Deep Networks via Gradient-Based Localization. 2017 IEEE International Conference on Computer Vision (ICCV). Published online October 2017. doi: 10.1109/iccv.2017.74
6. Chattopadhyay A, Sarkar A, Howlader P, Balasubramanian VN. Grad-CAM++: Improved Visual Explanations for Deep Convolutional Networks. *IEEE WACV*. 2018; 839-847. doi: 10.1109/WACV.2018.00097
7. Haq I, Mazhar T, Malik MA. Lung Nodules Localization and Report Analysis from Computerized Tomography (CT) Scan Using a Novel Machine Learning Approach. *Applied Sciences*. 2022; 12. doi: 10.3390/app 122412614
8. Echtioui A, Zouch W, Ghorbel M, et al. Detection Methods of COVID-19. *SLAS Technology*. 2020; 25(6): 566-572. doi: 10.1177/2472630320962002
9. Hussain M, Islam A, Turi JA, et al. Machine Learning-Driven Approach for a COVID-19 Warning System. *Electronics*. 2022; 11(23): 3875. doi: 10.3390/electronics11233875

10. Khadhraoui M, Bellaaj H, Ammar MB, et al. Survey of BERT-Base Models for Scientific Text Classification: COVID-19 Case Study. *Applied Sciences*. 2022; 12(6): 2891. doi: 10.3390/app12062891
11. Alsaed Z, Khweiled R, Hamad M, et al. Role of Blockchain Technology in Combating COVID-19 Crisis. *Applied Sciences*. 2021; 11(24): 12063. doi: 10.3390/app112412063
12. Guefrechi S, Jabra MB, Ammar A, et al. Deep learning based detection of COVID-19 from chest X-ray images. *Multimedia Tools and Applications*. 2021; 80(21-23): 31803-31820. doi: 10.1007/s11042-021-11192-5
13. Ben Jabra M, Koubaa A, Benjdira B, et al. COVID-19 Diagnosis in Chest X-rays Using Deep Learning and Majority Voting. *Applied Sciences*. 2021; 11(6): 2884. doi: 10.3390/app11062884
14. Geirhos R, Jacobsen JH, Michaelis C, et al. Shortcut learning in deep neural networks. *Nature Machine Intelligence*. 2020; 2(11): 665-673. doi: 10.1038/s42256-020-00257-z
15. Huang G, Liu Z, Van Der Maaten L, et al. Densely Connected Convolutional Networks. 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR). Published online July 2017. doi: 10.1109/cvpr.2017.243
16. Yang J, Shi R, Ni B. MedMNIST Classification Decathlon: A Lightweight AutoML Benchmark for Medical Image Analysis. 2021 IEEE 18th International Symposium on Biomedical Imaging (ISBI). Published online April 13, 2021. doi: 10.1109/isbi48211.2021.9434062
17. Al-Khawari H, Athyal RP, Al-Saeed O, et al. Inter- and intraobserver variation between radiologists in the detection of abnormal parenchymal lung changes on high-resolution computed tomography. *Annals of Saudi Medicine*. 2010; 30(2): 129-133. doi: 10.4103/0256-4947.60518
18. Xie Y, Chen M, Kao D, et al. "CheXplain. Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems. Published online April 21, 2020. doi: 10.1145/3313831.3376807
19. Venugopal VK, Takhar R, Gupta S, et al. Clinical Explainability Failure (CEF) & Explainability Failure Ratio (EFR) – Changing the Way We Validate Classification Algorithms. *Journal of Medical Systems*. 2022; 46(4). doi: 10.1007/s10916-022-01806-2
20. Jacovi A, Goldberg Y. Towards Faithfully Interpretable NLP Systems: How Should We Define and Evaluate Faithfulness? Proceedings of the 58th Annual Meeting of the Association for Computational Linguistics. Published online 2020. doi: 10.18653/v1/2020.acl-main.386
21. Tufail AB, Anwar N, Othman MTB, et al. Early-Stage Alzheimer's Disease Categorization Using PET Neuroimaging Modality and Convolutional Neural Networks in the 2D and 3D Domains. *Sensors*. 2022; 22(12): 4609. doi: 10.3390/s22124609
22. McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. *Nature*. 2020; 577(7788): 89-94. doi: 10.1038/s41586-019-1799-6
23. Lapuschkin S, Wäldchen S, Binder A, et al. Unmasking Clever Hans predictors and assessing what machines really learn. *Nature Communications*. 2019; 10(1). doi: 10.1038/s41467-019-08987-4
24. Raza A, Ayub H, Khan JA, et al. A Hybrid Deep Learning-Based Approach for Brain Tumor Classification. *Electronics*. 2022; 11(7): 1146. doi: 10.3390/electronics11071146
25. Kriegsmann M, Kriegsmann K, Steinbuss G, et al. Deep Learning in Pancreatic Tissue: Identification of Anatomical Structures, Pancreatic Intraepithelial Neoplasia, and Ductal Adenocarcinoma. *International Journal of Molecular Sciences*. 2021; 22(10): 5385. doi: 10.3390/ijms22105385
26. Sun X, Yin Y, Yang Q, et al. Artificial intelligence in cardiovascular diseases: diagnostic and therapeutic perspectives. *European Journal of Medical Research*. 2023; 28(1). doi: 10.1186/s40001-023-01065-y
27. Chlif M, Ammar MM, Said NB, et al. Mechanism of Dyspnea during Exercise in Children with Corrected Congenital Heart Disease. *International Journal of Environmental Research and Public Health*. 2021; 19(1): 99. doi: 10.3390/ijerph19010099
28. Chirica C, Haba D, Cojocar E, et al. One Step Forward—The Current Role of Artificial Intelligence in Glioblastoma Imaging. *Life*. 2023; 13(7): 1561. doi: 10.3390/life13071561
29. Moffat JG, Vincent F, Lee JA, et al. Opportunities and challenges in phenotypic drug discovery: an industry perspective. *Nature Reviews Drug Discovery*. 2017; 16(8): 531-543. doi: 10.1038/nrd.2017.111
30. Van den Broeck WMM. Drug Targets, Target Identification, Validation, and Screening. *The Practice of Medicinal Chemistry*. Published online 2015: 45-70. doi: 10.1016/b978-0-12-417205-0.00003-1
31. Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? *Drug Discovery Today*. 2011; 16(23-24): 1037-1043. doi: 10.1016/j.drudis.2011.09.007

32. Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? *Drug Discovery Today*. 2012; 17: S24-S30. doi: 10.1016/j.drudis.2011.12.008
33. Lindsay MA. Target discovery. *Nature Reviews Drug Discovery*. 2003; 2(10): 831-838. doi: 10.1038/nrd1202
34. Farhud DD, Zokaei S. Ethical Issues of Artificial Intelligence in Medicine and Healthcare. *Iranian Journal of Public Health*. Published online October 27, 2021. doi: 10.18502/ijph.v50i11.7600
35. EUR-Lex. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Available online: <https://eur-lex.europa.eu/eli/reg/2016/679/oj> (accessed on 12 March 2024).
36. American Society of Human Genetics (ASHG). The genetic information nondiscrimination act (GINA). Available online: <https://www.ashg.org/advocacy/gina/> (accessed on 12 March 2024).
37. Nordling L. A fairer way forward for AI in health care. *Nature*. 2019; 573(7775): S103-S105. doi: 10.1038/d41586-019-02872-2
38. The Guardian. RoboDoc: How India's robots are taking on Covid patient care. Available online: <https://www.theguardian.com/global-development/2020/dec/02/robodoc-how-india-robots-are-taking-on-covid-patient-care-mitra> (accessed on 12 March 2024).
39. Markose A, Krishnan R, Ramesh M. Medical ethics. *Journal of Pharmacy And Bioallied Sciences*. 2016; 8(5): 1. doi: 10.4103/0975-7406.191934
40. Varkey B. Principles of Clinical Ethics and Their Application to Practice. *Medical Principles and Practice*. 2020; 30(1): 17-28. doi: 10.1159/000509119
41. Amisha, Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. *J Family Med Prim Care*. 2019; 8(7): 2328-2331. doi: 10.4103/jfmpe.jfmpe_440_19
42. Farhud DD. Epigenetic and Ethics: How are Ethical Traits Inherited? *International Journal of Ethics & Society (IJES)*. 2019; 1: 1-4.